KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2016 - 2021)

Vertex Pharmaceuticals (VRTX) has 9 years of Long-Term Debt Issuances data on record, last reported at $10.0 million in Q4 2021.

  • For Q4 2021, Long-Term Debt Issuances rose 114.68% year-over-year to $10.0 million; the TTM value through Sep 2022 reached $10.0 million, down 42.06%, while the annual FY2021 figure was $22.6 million, 69.92% up from the prior year.
  • Long-Term Debt Issuances reached $10.0 million in Q4 2021 per VRTX's latest filing, up from $1.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $30.0 million in Q4 2017 and bottomed at $1.0 million in Q3 2021.
  • Average Long-Term Debt Issuances over 5 years is $7.2 million, with a median of $5.3 million recorded in 2017.
  • Peak YoY movement for Long-Term Debt Issuances: surged 131.53% in 2017, then plummeted 73.78% in 2018.
  • A 5-year view of Long-Term Debt Issuances shows it stood at $30.0 million in 2017, then tumbled by 73.78% to $7.9 million in 2018, then increased by 14.52% to $9.0 million in 2019, then crashed by 48.23% to $4.7 million in 2020, then skyrocketed by 114.68% to $10.0 million in 2021.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Issuances were $10.0 million in Q4 2021, $1.0 million in Q3 2021, and $8.0 million in Q2 2021.